The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice-Reference-Cited by-同舟云学术

The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice

Published:2020-07 Issue: Volume:71 Page:109605
ISSN:0898-6568
Container-title:Cellular Signalling
language:en
Short-container-title:Cellular Signalling

Author:

Brown Carolyn N.,Atwood Daniel J.,Pokhrel Deepak,Ravichandran Kameswaran,Holditch Sara J.,Saxena Sanskriti,Miyazaki Makoto,Nemenoff Raphael,Weiser-Evans Mary C.M.,Ljubanovic Danica Galesic,Joy Melanie S.,Edelstein Charles L.

Funder

Veterans Affairs Merit Award

Publisher

Elsevier BV

Subject

Cell Biology

Reference51 articles.

1. Pathophysiology of cisplatin-induced acute kidney injury;Ozkok;Biomed. Res. Int.,2014

2. Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury;Holditch;Int. J. Mol. Sci.,2019

3. CD4 T cell knockout does not protect against kidney injury and worsens cancer;Ravichandran;J. Mol. Med.,2016

4. IL-33 exacerbates acute kidney injury;Akcay;J. Am. Soc. Nephrol.,2011

5. IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer;Ravichandran;Am. J. Physiol. Renal Physiol.,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Trametinib in Alleviating Cisplatin-Induced Acute Kidney Injury: Inhibition of Inflammation, Oxidative Stress, and Tubular Cell Death in a Mouse Model;Molecules;2024-06-17

2. Evaluation of Cisplatin-Induced Acute Kidney Injury in Patients Coprescribed Serotonin Receptor Antagonists: A Retrospective Analysis;Kidney360;2024-05-30

3. Limonin, a natural ERK2 agonist, protects against ischemic acute kidney injury;International Journal of Biological Sciences;2023

4. No safe renal warm ischemia time—The molecular network characteristics and pathological features of mild to severe ischemia reperfusion kidney injury;Frontiers in Molecular Biosciences;2022-11-16

5. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition;Clinical Cancer Research;2022-03-01